SXI Life Sciences
6.905,90
PKT
+48,39
PKT
+0,71
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
29.03.05 | Roche Buy | Sarasin Research | |
24.03.05 | Roche Sector Outperform | Vontobel | |
23.03.05 | Kuros (Kuros Biosciences) Sector Outperform | Vontobel | |
22.03.05 | Siegfried Neutral | Helvea | |
22.03.05 | Roche Buy | Sarasin Research | |
21.03.05 | Novartis Neutral | Sarasin Research | |
21.03.05 | Novartis Kaufen | Helaba Trust | |
22.03.05 | Novartis Accumulate | Helvea | |
21.03.05 | Novartis Neutral | Sarasin Research | |
21.03.05 | Tecan (N) Sector Perform | Vontobel | |
17.03.05 | Roche In-Line | Goldman Sachs | |
17.03.05 | Novartis Outperform | Goldman Sachs | |
17.03.05 | Tecan (N) Reduce | Helvea | |
17.03.05 | Roche Buy | Helvea | |
11.03.05 | Novartis Neutral | Sarasin Research | |
11.03.05 | Novartis Buy | Helvea | |
10.03.05 | Novartis Neutral | Sarasin Research | |
10.03.05 | Roche Buy | Sarasin Research | |
09.03.05 | Novartis Buy | Merrill Lynch | |
07.03.05 | Roche Neutral | Helvea | |
08.03.05 | Novartis Neutral | Sarasin Research | |
08.03.05 | Roche Neutral | Helvea | |
01.03.05 | Roche Buy | Sarasin Research | |
24.02.05 | Novartis Overweight | Lehman Brothers | |
22.02.05 | Novartis Buy | Helvea | |
23.02.05 | Novartis Outperform | Goldman Sachs | |
21.02.05 | Straumann Outperform | Goldman Sachs | |
22.02.05 | Novartis Kaufen | Helaba Trust | |
22.02.05 | Novartis Hold | SEB | |
21.02.05 | Novartis Neutral | Sarasin Research | |
21.02.05 | Novartis Buy | Helvea | |
22.02.05 | Novartis Akkumulieren | Independent Research | |
21.02.05 | Straumann Accumulate | Helvea | |
21.02.05 | Straumann Underweight | Lehman Brothers | |
18.02.05 | Lonza Buy | Helvea | |
17.02.05 | Roche Hold | Crédit Suisse | |
17.02.05 | Straumann Outperform | Credit Suisse First Boston | |
17.02.05 | Lonza Reduce | Sarasin Research | |
17.02.05 | Kuros (Kuros Biosciences) Neutral | Helvea | |
16.02.05 | Lonza Buy | Helvea |